Home›Trial›NCT04119050
🔬NCT04119050Phase 2Phase 3ACTIVE NOT RECRUITING

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

Study Summary

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Conditions
Warm Autoimmune Hemolytic Anemia
Interventions / Drugs
M281Placebo
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment118 participants
Primary Completion—
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.550656+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.